Accretion Pharmaceuticals Ltd. · NSE:ACCPL
Accretion Pharmaceuticals — H1 FY2027 Earnings Presentation
27 slides from Accretion Pharmaceuticals's earnings presentation, Nov 3, 2026
Slide 1: Exchange filing cover letter for investor presentation
Date: 03rd November, 2026 To, Corporate Relations Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Company Code: ACCPL Dear Sir/ Madam, Subject: Investors/ Analysts Presentation for the half - year ended on 30th Sept
Slide 2: Investor Presentation H1 FY 2027
INVES TOR PRESENTATION H1 FY 202 7 2025 June PHARMACEUTICALS LIMITED
Slide 3: Disclaimer
DISCLAIMER This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Pharmaceuticals Limited (ACCPL) and its group companies’ future business developments a
Slide 4: Table of Content
TABLE OF Company Overview 01 Shareholding Overview 02 Business Overview 03 CONTENT Financial Highlights Strategic Roadmap 04 05
Slide 5: Company Overview
COMPANY OVERVIEW er Pe
Slide 6: Accretion Pharmaceuticals Limited in Nutshell
ACCRETION PHARMACEUTICALS LIMITED IN NUTSHELL Quality Manufacturing. Global Ambition. Founded in 2012, Accretion Pharmaceuticals Limited has evolved into a growing Indian pharmaceutical enterprise, listed on NSE Emerge in FY 2025–26. With a modern, state-of-the-art manufacturing facility in Ahmedaba
Slide 7: Shareholding Overview
SHAREHOLDING OVERVIEW er Pe
Slide 8: Shareholding Overview
SHAREHOLDING OVERVIEW Symbol of Company at NSE Emerge ACCPL 30th September, 2026 Category of Investor No. of Shareholders No. of Shares held Holding (%) Promoter Shareholding 9 8172400 73.52 % Public Shareholding 710 2943600 26.48 % Total 719 11116000 100% Stock Information as on 30th September, 202
Slide 9: Business Overview
BUSINESS OVERVIEW er Pe
Slide 10: Our Founders – Classroom to Boardroom
OUR FOUNDERS – CLASSROOM TO BOARDROOM Visionary Leadership. Momentum Built. What began with shared classrooms and a shared vision has evolved into a growing pharmaceutical enterprise. The founders, who began their journey as Pharmacy students, have transformed their academic expertise into entrepren
Slide 11: Our Journey So Far
OUR JOURNEY SO FAR YEAR 2026 Renewed WHO-cGMP certification and obtained GLP certificate. YEAR 2024 Received cGMP (Current Good Manufacturing Practices) approval from regulatory authorities of Rwanda and Congo (DR) for its manufacturing facility. YEAR 2022 Received cGMP (Current Good Manufacturing P
Slide 12: Core Strengths
CORE STRENGTHS Built on Quality. Driven by Capability. Positioned for Growth. QUALITY - DRIVEN CERTIFICATIONS & COMPLIANCE: MANUFACTURING: A commitment to quality, safety and Modern manufacturing infrastructure operational excellence, supported by supported by robust quality WHO-cGMP, GLP, FSSAI, FS
Slide 13: Building a Strong Presence Since 2012
BUILDING A STRONG PRESENCE SINCE 2012 Presence over 30+ countries across Global Markets.
Slide 14: Our Business Model
OUR BUSINESS MODEL ACCPL operates a diversified business model comprising CDMO Services, Own Brand Exports and Product Development Technology Transfer enabling a balance between stability and strategic growth. ACCPL provides Contract Development and Manufacturing (CDMO) services to domestic and inte
Slide 15: Product by Dosage Forms
PRODUCT BY DOSAGE FORMS TABLETS CAPSULES ORAL EXTERNAL ORAL LIQUIDS PREPARATIONS POWDER
Slide 16: Therapeutic Segment
THERAPEUTIC SEGMENT Anti- Antibiotic Antibacterial Antifungal Antihistamine Antiallergics Anticold Inflammatory Vitamins and Anti-diabetic Cardiac Psychotropic Antitussives Aantiparasitic Aantiemetic Supplement Laxative Antipruritic Antiulcer Antacid Anti-Malerial Anti- Antiseptic Hypertensive
Slide 17: Financial Highlights
FINANCIAL HIGHLIGHTS er Pe
Slide 18: Founders' Message
FOUNDERS’ MESSAGE H1 FY27 has been a period of strong growth for Accretion Pharmaceuticals Limited. The Company achieved revenue of ₹55.04 crore, registering 25.83% year-on-year growth. EBITDA (including other income) grew by 72.28% to ₹12.37 crore, while PAT increased by 72.63% to ₹8.20 crore. The
Slide 19: Performance Highlight (H1 FY 2027) and Revenue Breakup
TOTAL INCOME – ₹ 55.04 Crore (25.83%YoY) PERFORMANCE HIGHLIGHT EBITDA (including other income) - (H1 FY 2027) ₹12.37 Crore (72.28 %YoY) PAT – ₹8.20 Crore (72.63%YoY) REVENUE BREAKUP DOMESTIC SALES - 81.85 % (H1 FY 2027) EXPORT SALES - 18.15 %
Slide 20: Revenue Composition (Half Yearly)
REVENUE COMPOSITION (HALF YEARLY) H1 Financial year – 2026-27 18.15% 9.16% 81.85% 90.84% H1 Financial year – 2025-26 Domestic Sales Exports
Slide 21: Revenue Composition (Yearly)
REVENUE COMPOSITION (YEARLY) Financial year – 2024-25 8.55% 8.30% 7.28% 91.70% 92.72% 91.45% Financial year – 2025-26 Financial year – 2023-24 Domestic Sales` Exports
Slide 22: Profit and Loss Statement
PROFIT AND LOSS STATEMENT Particulars (₹ in Crore) H1 FY27 H1 FY26 YoY% H2 FY26 FY26 Income from Operations 55.04 43.74 25.83% 45.89 89.63 Other Income 0.15 0.11 0.08 0.19 Total Income from Operations 55.18 43.85 25.84% 45.97 89.82 37.51 Raw Materials 32.16 33.00 65.16 Revenue from operations increa
Slide 23: Financial Highlights – Half Yearly
FINANCIAL HIGHLIGHTS – HALF YEARLY EBITDA (₹ in Crore)/ PAT (₹ in Crore)/ REVENUE (₹ in Crore) Net Worth (₹ in Crore) Margin (%) Margin (%) 16.42% 10.87% 7.2 4.8 43.74 46.6 55.04 62.9 12.4 8.2 22.48% 14.90% H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27
Slide 24: Financial Highlights – Annually (FY26)
FINANCIAL HIGHLIGHTS – ANNUALLY (FY26) Revenue (₹ Cr) EBITDA (₹ Cr) / Margin (%) 16 23.1% 25% 15.2 89.6 14 20.9% 20% 12 16.9% 11.9 10 15% 57.4 8 8.7% 7.8 10% 6 7.3% 33.7 29.4 22.3 4 5% 2 1.9 2.1 0 0% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 PAT (₹ Cr) / Margin (%) Net Worth (₹ Cr) 12 14% 54
Slide 25: Strategic Roadmap
STRATEGIC ROADMAP er Pe
Slide 26: Strategic Roadmap
STRATEGIC ROADMAP C A P E X – The proposed capital expenditure involves leasing additional land adjacent to the existing facility and investing in new machinery and equipment to expand production capacity. This investment will support infrastructure development, improve operational efficiency, and e
Slide 27: Listed on NSE Emerge
LISTED ON NSE EMERGE ACCRETION PHARMACEUTICALS LIMITED CS ROSHNI SHAH I COMPANY SECRETARY & COMPLIANCE OFFICER E-MAIL: COMPLIANCE@ACCRETIONPHARMA.COM WWW.ACCRETIONPHARMA.COM
Accretion Pharmaceuticals — H1 FY2027 Earnings Presentation on 6ix